Cargando…
Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
The 2017 PACIFIC trial heralded the incorporation of routine adjuvant durvalumab following curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However, carefully selected clinical trial populations can differ significantly from real-world populations, which can have impl...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453685/ https://www.ncbi.nlm.nih.gov/pubmed/37623040 http://dx.doi.org/10.3390/curroncol30080559 |
_version_ | 1785095997647486976 |
---|---|
author | Preti, Beatrice T. B. Sanatani, Michael S. Breadner, Daniel Lakkunarajah, Suganija Scott, Carolyn Esmonde-White, Caroline McArthur, Eric Rodrigues, George Chaudhary, Mitali Mutsaers, Adam Sachdeva, Robin Vincent, Mark D. |
author_facet | Preti, Beatrice T. B. Sanatani, Michael S. Breadner, Daniel Lakkunarajah, Suganija Scott, Carolyn Esmonde-White, Caroline McArthur, Eric Rodrigues, George Chaudhary, Mitali Mutsaers, Adam Sachdeva, Robin Vincent, Mark D. |
author_sort | Preti, Beatrice T. B. |
collection | PubMed |
description | The 2017 PACIFIC trial heralded the incorporation of routine adjuvant durvalumab following curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However, carefully selected clinical trial populations can differ significantly from real-world populations, which can have implications on treatment toxicities and outcomes, making it difficult to accurately counsel patients. Consequently, we performed a real-world, retrospective analysis of outcomes and toxicities in 118 patients with stage III NSCLC treated with durvalumab after platinum-based chemoradiotherapy. The data were collected from patients who underwent treatment at a single, tertiary-level Canadian cancer centre from May 2018 to October 2020. The variables collected included patient demographics, treatment specifics, progression-free survival, overall survival, and immune-related adverse events (IRAE) from durvalumab. Descriptive statistics were used for toxicity analysis, and progression-free survival and overall survival estimates were calculated using the Kaplan–Meier method. The statistical analyses indicated a 64.4% (n = 76) toxicity rate, with a 21% (n = 25) toxicity rate of grade 3+ IRAEs. The most common documented IRAEs were pneumonitis (n = 44; 40%), followed by rash (n = 20; 18%) and thyroid dysfunction (n = 17; 15%). FEV1 and DLCO were not found to be associated predictors of pneumonitis toxicity. The median PFS and OS were estimated to be >1.7 years and >2.7 years, respectively. |
format | Online Article Text |
id | pubmed-10453685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104536852023-08-26 Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer Preti, Beatrice T. B. Sanatani, Michael S. Breadner, Daniel Lakkunarajah, Suganija Scott, Carolyn Esmonde-White, Caroline McArthur, Eric Rodrigues, George Chaudhary, Mitali Mutsaers, Adam Sachdeva, Robin Vincent, Mark D. Curr Oncol Communication The 2017 PACIFIC trial heralded the incorporation of routine adjuvant durvalumab following curative-intent chemoradiation for stage III non-small-cell lung cancer (NSCLC). However, carefully selected clinical trial populations can differ significantly from real-world populations, which can have implications on treatment toxicities and outcomes, making it difficult to accurately counsel patients. Consequently, we performed a real-world, retrospective analysis of outcomes and toxicities in 118 patients with stage III NSCLC treated with durvalumab after platinum-based chemoradiotherapy. The data were collected from patients who underwent treatment at a single, tertiary-level Canadian cancer centre from May 2018 to October 2020. The variables collected included patient demographics, treatment specifics, progression-free survival, overall survival, and immune-related adverse events (IRAE) from durvalumab. Descriptive statistics were used for toxicity analysis, and progression-free survival and overall survival estimates were calculated using the Kaplan–Meier method. The statistical analyses indicated a 64.4% (n = 76) toxicity rate, with a 21% (n = 25) toxicity rate of grade 3+ IRAEs. The most common documented IRAEs were pneumonitis (n = 44; 40%), followed by rash (n = 20; 18%) and thyroid dysfunction (n = 17; 15%). FEV1 and DLCO were not found to be associated predictors of pneumonitis toxicity. The median PFS and OS were estimated to be >1.7 years and >2.7 years, respectively. MDPI 2023-08-18 /pmc/articles/PMC10453685/ /pubmed/37623040 http://dx.doi.org/10.3390/curroncol30080559 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Preti, Beatrice T. B. Sanatani, Michael S. Breadner, Daniel Lakkunarajah, Suganija Scott, Carolyn Esmonde-White, Caroline McArthur, Eric Rodrigues, George Chaudhary, Mitali Mutsaers, Adam Sachdeva, Robin Vincent, Mark D. Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer |
title | Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer |
title_full | Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer |
title_fullStr | Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer |
title_full_unstemmed | Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer |
title_short | Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer |
title_sort | real-world analysis of durvalumab after chemoradiation in stage iii non-small-cell lung cancer |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453685/ https://www.ncbi.nlm.nih.gov/pubmed/37623040 http://dx.doi.org/10.3390/curroncol30080559 |
work_keys_str_mv | AT pretibeatricetb realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer AT sanatanimichaels realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer AT breadnerdaniel realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer AT lakkunarajahsuganija realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer AT scottcarolyn realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer AT esmondewhitecaroline realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer AT mcarthureric realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer AT rodriguesgeorge realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer AT chaudharymitali realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer AT mutsaersadam realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer AT sachdevarobin realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer AT vincentmarkd realworldanalysisofdurvalumabafterchemoradiationinstageiiinonsmallcelllungcancer |